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Article focus
  What is the available clinical level of evi-
dence that supports the use of demineral-
ised bone matrix (DBM) in trauma and 
orthopaedic surgery?
Key messages
  The majority of the available clinical level 
evidence supporting the use of DBM prod-
ucts in trauma and orthopaedic surgery 
consist of case series (level Iv evidence).
  The use of DBM products has been most 
extensively investigated in spinal sur-
gery, with level I evidence that supports 
the use of Grafton DBM (osteotech, 
Eatontown, New Jersey) as a bone graft 
extender in posterolateral lumbar fusion 
surgery.
  The use of DBM products is not well 
investigated in trauma surgery, with only 
case series that mainly describe the use 
of Allomatrix (Wright Medical, london, 
The available evidence on demineralised 
bone matrix in trauma and orthopaedic 
surgery
A sysTEMATIc rEvIEW
Objectives
The aim of this systematic literature review was to assess the clinical level of evidence of 
commercially available demineralised bone matrix (DBM) products for their use in trauma 
and orthopaedic related surgery.
Methods
A total of 17 DBM products were used as search terms in two available databases: embase 
and pubMed according to the preferred Reporting Items for systematic Reviews and Meta 
Analyses statement. All articles that reported the clinical use of a DBM-product in trauma 
and orthopaedic related surgery were included.
Results
The literature search resulted in 823 manuscripts of which 64 manuscripts met the final 
inclusion criteria. The included manuscripts consisted of four randomised controlled tri-
als (level I), eight cohort studies (level III) and 49 case-series (level IV). no clinical studies 
were found for ten DBM products, and most DBM products were only used in combination 
with other grafting materials. DBM products were most extensively investigated in spinal 
surgery, showing limited level I evidence that supports the use Grafton DBM (osteotech, 
eatontown, new Jersey) as a bone graft extender in posterolateral lumbar fusion surgery. 
DBM products are not thoroughly investigated in trauma surgery, showing mainly level IV 
evidence that supports the use of Allomatrix (Wright Medical, London, United Kingdom), 
DBX (Depuy synthes, Zuchwil, switzerland), Grafton DBM, or orthoBlast (citagenix Laval, 
canada) as bone graft extenders.
Conclusions
The clinical level of evidence that supports the use of DBM in trauma and orthopaedic 
surgery is limited and consists mainly of poor quality and retrospective case-series. More 
prospective, randomised controlled trials are needed to understand the clinical effect and 
impact of DBM in trauma and orthopaedic surgery.
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united Kingdom), DBX (DePuy synthes, Zuchwil, 
switzerland), Grafton DBM, and orthoBlast (citagenix 
laval, canada) as bone graft extenders in trauma sur-
gery (level III/Iv evidence).
Strengths and limitations
  Product-specific overview of DBM used for specific 
trauma- and orthopaedic-related indications.
  Inclusion of a large number of papers describing the 
clinical outcomes of DBM products used in trauma 
and orthopaedic surgery
  Not all DBM products that are commercially available 
worldwide could be included.
Introduction
Bone grafting is a common procedure in trauma and 
orthopaedic surgery, with more than two million proce-
dures being performed worldwide each year.1 Autologous 
bone is the gold standard grafting material and it is 
mostly harvested from the iliac crest. However, this har-
vesting procedure has a considerable morbidity rate (8% 
to 39%),2 and the amount of bone that can be harvested 
is not always sufficient. These issues resulted in the devel-
opment of alternative bone graft materials. These alterna-
tive bone graft materials have been used as a bone graft 
extender (reinforcing autologous bone) or as a bone graft 
substitute (replacing autologous bone).
Demineralised bone matrix (DBM) is processed alloge-
neic bone that has been demineralised by extensive 
decalcification procedures. These procedures include 
chemical and radiation steps to minimise immunogenic 
response and the risk of infection.3 The resulting material 
consists of matrix proteins containing certain quantities 
of osteo-inductive growth factors (e.g. bone morphoge-
netic proteins). In 1965, urist4 showed that DBM main-
tains its osteo-inductive potential, since subcutaneous 
implantation led to de novo bone formation in rabbits 
This was later confirmed by Geesink et  al5 in a small 
human series, where five out of six critical fibular bone 
defects were successfully treated with DBM. However, 
whether these osteo-inductive properties can be consist-
ently reproduced in a DBM product remains heavily 
debated.6 The preserved amount of bone morphogenetic 
protein (BMP) after demineralisation merely lies within 
the nanogram range and, moreover, the absolute amount 
of BMP per DBM product varies up to fourfold between 
various batches of the same DBM product.7-9
Nevertheless, many trauma and orthopaedic surgeons 
consider DBM to be a useful bone graft substitute for a 
wide range of clinical indications in trauma and ortho-
paedic surgery. subsequently, the number of commer-
cially available DBM products is constantly increasing, 
which is possible due to favourable regulatory pathways 
that allow quick access of new products onto the clinical 
market (i.e. DBMs are not regulated under 510(k) 
regulation, but are considered minimally manipulated 
tissue for transplantation). Nevertheless, there is no 
 evidence-based guideline available that assists trauma 
and orthopaedic surgeons in making evidence-based 
decisions regarding the use of DBM products in different 
clinical indications. Therefore, the aim of this systematic 
review was to provide the clinical level of evidence that 
supports the use of DBM products in trauma- and 
 orthopaedic-related surgery.
Materials and Methods
Literature search. Product names of commercially avail-
able DBM products in the Netherlands (Table I) were 
used as search terms in two available online databases: 
PubMed and Embase. The search key used for PubMed 
was: “(product name) AND bone[Title/Abstract]” and 
for Embase, it was: “product name AND bone:ab,ti”. The 
databases were searched from the earliest date available 
until 01 January 2017. Independently, two research-
ers (Jvds and KAH) performed the search. Manuscripts 
describing original studies on the use of DBM products 
written in English, German and Dutch were considered 
eligible. In order to select manuscripts primarily con-
cerning the clinical use of DBM products for trauma- 
and orthopaedic-related indications, manuscripts were 
excluded if they only contained in vitro data or animal 
experiments or reported on the use of DBM products in 
non-orthopaedic-related indications (e.g. dental or max-
illofacial surgery). references in the selected manuscripts 
were reviewed in order to ensure that no papers were 
missed with the chosen search strategy. All included 
manuscripts were assigned a level of evidence by two 
agreeing reviewers (Jvds and KAH) for their use as a bone 
graft extender or bone graft substitute, as described by 
Wright et al10 (Table II).
Results
Literature search. The initial literature search in PubMed 
and Embase resulted in a total of 823 papers. After screen-
ing all titles and abstracts, 101 manuscripts from PubMed 
and 140 manuscripts from Embase were considered eli-
gible. Exclusion of duplicate articles resulted in a total of 
149 eligible manuscripts. of these 149 eligible manu-
scripts, 93 were excluded based on the exclusion crite-
ria described, and eight manuscripts were added based 
upon the reference list. This resulted in a final number 
of 64 manuscripts that fulfil all selection criteria (Fig. 1). 
A detailed overview specified per product is provided in 
Table III.
Orthopaedic-related indications. DBM products have 
been used as a bone graft extender or as a bone graft 
substitute for a wide range of trauma- and orthopaedic-
related indications (Table Iv). Most studies were case 
series (n = 49); there were only four randomised control 
trials (rcTs) and eight cohort studies. The remaining three 
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studies reported the random use of DBM products among 
different study groups without reporting outcomes related 
to the use of DBM.11-13 The number of clinical studies per 
DBM product varies extensively. The most frequently 
examined DBM products, Grafton DBM (osteotech. 
Eatontown, New Jersey) and Allomatrix (Wright Medical, 
london, united Kingdom), were described in 33 and 18 
studies, respectively. No clinical studies were found for 
ten of the 15 remaining DBM products.
Spine surgery. Four DBM products have been used in spi-
nal surgery: Accell connexus (citagenix, laval, canada); 
Allomatrix; Grafton DBM; and osteofil (Medtronic, 
Minneapolis, Minnesota). These DBM products were 
used as bone graft extenders in most studies; only in 
two studies45,46 was Grafton DBM used as a bone graft 
substitute.
Lumbar spinal fusion. Accell connexus was used as a 
bone graft extender in instrumented posterolateral 
lumbar fusions in 33 patients.14 In this randomised 
study, iliac crest bone was augmented with a mixture 
of Accell connexus and autologous bone marrow aspi-
rate, and compared with the use of iliac crest bone 
alone. After one year, grafting had resulted in similar 
fusion rates (70% versus 76%). There was no difference 
Table I. Product specifications of commercially available demineralised bone matrix (DBM)
Product Manufacturer DBM % Carrier Form FDA Indication
Accell Connexus citagenix, laval, canada 70 reverse phase medium Paste 510(k) Bone void filler/bone 
graft extender
Accell TBM Integra, Irvine, california 100 - strips 510(k) Bone void filler/bone 
graft extender
AlloCraft stryker, Mahwah, New Jersey 80 Acellular matrix Paste 510(k) Bone void filler
Allomatrix Wright Medical, london, united 
Kingdom
40 to 86 calcium sulphate Paste 510(k) Bone void filler
AlphaGRAFT Alphatech, carlsbad, california 80 Acellular matrix Paste 510(k) Bone void filler
Altiva Exactech, Gainesville, Florida ND Gelatin Paste 510(k) Bone void filler
BioSet Penta Biomedical, verona, Italy 24 Gelatin Paste/strips 510(k) Bone void filler
DBX DePuy synthes, Zuchwil, 
switzerland
32 Hyaluronic acid Paste/strips 510(k) Bone graft extender/bone 
void filler
Grafton DBM osteotech, Eatontown, New Jersey 17 to 31 Glycerol Paste/strips 510(k) Bone graft substitute/
bone graft extender/bone 
void filler
InterGro Zimmer Biomet., Westminster, 
california
40 lecithin Paste 510(k) Bone graft extender/bone 
void filler
Optefil Exactech 24 Gelatin Paste 510(k) Bone void filler
Opteform Exactech ND cortical and cancellous bone 
chips suspended in collagen-
gelatin
Paste 510(k) Bone void filler
Optium DBM DePuy, Warsaw, Indiana ND Glycerol Paste 510(k) Bone void filler
OrthoBlast citagenix ND reverse phase medium Paste 510(k) Bone void filler/bone 
graft extender
OrthoBlast II citagenix 20 reverse phase medium Paste 510(k) Bone void filler/bone 
graft extender
Osteofil Medtronic, Minneapolis, Minnesota 24 collagen Paste/strips 510(k) Bone void filler
VIAGRAF smith & Nephew, london, united 
Kingdom
ND Glycerol Paste/strips 510(k) Bone void filler
FDA, Food and Drug Administration; ND, no data available
Table II. level of evidence as described by Wright et al10
Level of evidence Type of study
I 1. rcT
2. systematic review of level I rcT
II 1. Prospective cohort study
2. Poor-quality rcT
3. systematic review level II studies
III 1. case-control study
2. retrospective cohort study
3. systematic review of level III studies
Iv case series (no, or historical, control group)
v Expert opinion
rcT, randomised control trial
Initial
search
Eligibility
Inclusion
Pubmed
(n = 242)
Embase
(n = 581)
(n = 101) (n = 140)
Duplicates
(n = 92) 
Eligible articles (n = 149) 
Exclusion
(n = 93)
- in vitro experiments (n = 18)
- animal experiments (n = 56)
- non-trauma or orthopaedic
related indication (n = 19) 
Additional references (n = 8)
Included articles
(n = 64) 
Fig. 1
Flowchart of manuscript selection.
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in pain or duration of surgery on the visual analogue 
scale (vAs). This study provides level II evidence that 
Accell connexus may be used as a bone graft extender 
for lumbar spinal fusion.
Allomatrix has been used in posterolateral lumbar 
fusions. Fu et  al15 showed in a case-control study that 
Allomatrix or autologous bone resulted in comparable 
fusion rates when used with hydroxyapatite/tricalci-
umphosphate granules: 81% fusion with Allomatrix and 
86% fusion with autologous bone respectively. Girardi 
and cammisa16 described a retrospective case series of 
65 patients where Allomatrix was mixed (1:1) with iliac 
crest bone. radiological follow-up showed an improve-
ment in the lenke scores, 3.7 after one month to 1.6 
after 12 months. In another retrospective case series13 
following 32 patients who underwent posterior lumbar 
interbody fusion for 36 months (18 to 42), clinical and 
radiological scores improved significantly. At the latest 
follow-up, the mean oswestry Disability Index improved 
from 52% to 22%. The mean roland-Morris Disability 
Questionnaire improved from 52% to 29%, while > 90% 
of the operated levels were fused. These studies provide 
level III evidence that Allomatrix may be used as a bone 
graft extender for lumbar spinal fusion.
Grafton DBM was studied as a bone graft extender for 
posterolateral spinal fusion in a rcT by cammisa et al in 
2004.35 In 120 patients, posterolateral lumbar fusions 
were carried out with pedicle screw fixation and one side 
of the spine was grafted with autograft (17.2 standard 
deviation (sd) 9.7 ml), while the contralateral side was 
grafted with autograft and Grafton DBM (17.2 sd 9.7 ml, 
mixed 1:2). After two years, autograft with Grafton DBM 
resulted in fusion in 42 cases (52%) and autograft alone 
resulted in fusion of 44 cases (54%). In another prospec-
tive cohort study,36 patients undergoing instrumented 
posterolateral lumbosacral spinal fusion were grafted 
with Grafton DBM and aspirated bone marrow (19 cases), 
Grafton DBM and autologous bone (27 cases), or autolo-
gous bone alone (27 cases). All groups showed similar 
fusion rates after two years’ follow-up (63%, 70% and 
67%, respectively). use of Grafton DBM as a bone graft 
extender in posterolateral lumbar fusions is further 
described in three other studies37-39 encompassing 138 
patients in total, where fusion rates after more than two 
years’ follow-up ranged from 86% (Kang et al37) to 93% 
(Thalgott et al38). These studies include level I evidence 
that Grafton DBM can be used as a bone graft extender 
for lumbar spinal fusion.
Table III. search results of systematic literature search
Products Inclusion Exclusion Final
PubMed Embase In vitro 
experiments
Animal 
experiments
Non-trauma- or 
orthopaedic-
related 
indication
Additional 
referencespapers (n) Eligible papers (n) Eligible Duplicates Total
Accell Connexus 
(citagenix, laval, canada)
2 2 7 3 1 4 1 2 0 0 1
Accell TBM (Integra, Irvine, 
california)
0 0 3 1 0 1 1 0 0 0 0
AlloCraft (stryker, 
Mahwah, New Jersey)
1 1 1 1 1 1 0 1 0 0 0
Allomatrix (Wright 
Medical, london, united 
Kingdom)
13 13 52 24 13 24 3 6 1 4 18
AlphaGRAFT (Alphatech, 
carlsbad, california)
0 0 0 0 0 0 0 0 0 0 0
Altiva (Exactech, 
Gainesville, Florida)
1 1 3 1 1 1 0 0 1 0 0
BioSet (Penta Biomedical, 
verona, Italy)
2 2 5 2 2 2 0 2 0 0 0
DBX (DePuy synthes, 
Zuchwil, switzerland)
25 24 66 31 20 35 6 18 6 0 5
Grafton DBM (osteotech, 
Eatontown, New Jersey)
181 46 371 57 42 61 5 20 6 3 33
InterGro (Zimmer Biomet, 
Westminster, california)
1 1 5 2 1 2 1 1 0 0 0
Optefil (Exactech) 0 0 0 0 0 0 0 0 0 0 0
Opteform (Exactech) 0 0 16 2 0 2 0 1 0 1 2
Optium DBM (DePuy. 
Warsaw, Indiana)
0 0 2 0 0 0 0 0 0 0 0
OrthoBlast (citagenix) 7 4 20 5 4 5 1 0 1 0 3
OrthoBlast II (citagenix) 4 4 4 4 4 4 0 0 4 0 0
Osteofil (Medtronic. 
Minneapolis, Minnesota)
5 4 25 8 4 8 1 5 0 0 2
VIAGRAF (smith & 
Nephew. london, united 
Kingdom)
0 0 1 0 0 0 0 0 0 0 0
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osteofil was used as a bone graft extender for one-
level (95 cases) and two-level (45 cases) posterolateral 
spinal fusions in a study from Epstein and Epstein.63 In 
this study, osteofil was mixed (1:1) with autologous 
bone, and patient outcome was assessed by the sF-36 
Questionnaire. one year post-operatively, clinical improve-
ment was observed on six out of eight health scales of the 
sF-36 Questionnaire. In one-level fusion, 2D-cT showed 
fusion rates of 93% after an average of 5.2 (sd)1.8 
months. Two patients required secondary surgery to 
treat nonunion or instability. In two-level fusion, 2D-cT 
showed fusion rates of 92% after an average of 6.1 sd 1.9 
months. Again, two patients required secondary surgery 
due to nonunion or instability.63 These studies provide 
level Iv evidence that osteofil may be used as a bone 
graft extender for lumbar spinal fusion.
Cervical spinal fusion. DBM products used in anterior cer-
vical fusions include Allomatrix, Grafton DBM and osteofil.
Allomatrix was used as a bone graft substitute in a 
study that included 29 patients suffering from craniocervi-
cal spine instability requiring occipitocervical fusion (ocF) 
due to trauma, rheumatoid arthritis or neoplasms.65 Two 
instrumentation techniques were compared (screw-rod 
instrumentation versus hook-and-screw-rod instrumenta-
tion), although the authors mention that Allomatrix was 
used in most cases. In fact, neither graft-specific outcome, 
nor graft-related complications were mentioned. This 
study provides no graft-specific outcomes on the use of 
Allomatrix as a bone graft substitute for cervical spinal 
fusions.
Grafton DBM was used in a rcT by An et al41 which 
included 77 patients undergoing anterior cervical fusion. 
Grafton DBM was combined with tricortical allografts 
and this was compared with tricortical autografts alone. 
Nonunion developed in 46% of patients who were 
grafted with Grafton DBM and tricortical allografts, com-
pared with only 26% of patients who received a tricortical 
autograft (p = 0.11), suggesting that the combination of 
Grafton DBM and allograft results in a higher rate of non-
union. Grafton DBM was also used to fill, partially42 or 
fully,45 polyetheretherketone (PEEK) cages used for cervi-
cal fusion. Park et al42 used PEEK cages containing autolo-
gous bone chips and Grafton DBM for cervical fusion of 
42 levels in 31 patients. After one year, a fusion rate of 
Table IV. clinical level of evidence of commercially available demineralised bone matrix (DBM)
Products Spine surgery Trauma surgery Orthopaedic surgery
lumbar cervical Thoracic Acute 
fractures
Nonunions Arthrodesis Avascular 
necrosis
reconstructive 
surgery
Tumour 
surgery
Accell Connexus 
(citagenix, laval, canada)
Ext: II14  
Accell TBM (Integra, 
Irvine, california)
 
AlloCraft (stryker, 
Mahwah, New Jersey)
 
Allomatrix (Wright 
Medical, london, united 
Kingdom)
Ext: III15,  
Ext: Iv16
*sub: I17,  
sub: Iv18-20
Ext: Iv21,  
sub: Iv22,23
Ext: Iv24 Ext: Iv25,26 Ext: Iv27, 
sub: Iv23,28,29
AlphaGRAFT (Alphatech, 
carlsbad, california)
 
Altiva (Exactech, 
Gainesville, Florida)
 
BioSet (Penta Biomedical, 
verona, Italy)
 
DBX (DePuy synthes, 
Zuchwil, switzerland)
sub: Iv30,31 sub: Iv32 sub: Iv33,34
Grafton DBM (osteotech, 
Eatontown, New Jersey)
Ext: I35,  
Ext: II36,  
Ext: III37,  
Ext: Iv38-40
*Ext: I41,  
Ext: Iv42-44, 
sub: Iv45
sub: III46 Ext: II47,  
Ext: III48,  
Ext: Iv21,49-52
Ext: II47, Ext: III53, 
Ext: Iv21,  
sub: III54,  
sub: Iv49
Ext: Iv55,56 Ext: Iv57 Ext58 Ext: Iv59, 
sub: Iv60-62
InterGro (Zimmer 
Biomet, Westminster, 
california)
 
Optefil (Exactech)  
Opteform (Exactech)  
Optium DBM (DePuy. 
Warsaw, Indiana)
 
OrthoBlast (citagenix) Ext: III48,  
Ext: Iv49
Ext: Iv55  
OrthoBlast II (citagenix)  
Osteofil (Medtronic, 
Minneapolis, Minnesota)
Ext: Iv63 Ext: Iv64  
VIAGRAF (smith & 
Nephew, london, united 
Kingdom)
 
Information presented as bone graft type followed by level of evidence number as described by Wright et al10
*DBM performance inferior to that of control group used
Ext, bone graft extender; sub, bone graft substitute
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97% was observed. Both the vAs score for neck and arm 
pain and the modified Japanese orthopaedic Association 
(JoA) scoring system for myelopathy were significantly 
improved. Elsawaf et al45 describe complete filling of the 
PEEK cage with Grafton DBM in anterior cervical discec-
tomy and fusion in a case series of 20 patients; the mean 
cobb angle improved (3.4° pre-operatively vs 14.5° post-
operatively) and JoA myelopathy scores and neck disabil-
ity index also subsequently improved. These studies 
include level I evidence that Grafton DBM is not useful as 
a bone graft extender for cervical spinal fusion.
osteofil was mixed with autologous bone (n = 11) in 
a study by Epstein,64 which also included 24 patients in 
which vitoss (β-tricalcium phosphate) was mixed with 
autologous bone. radiological follow-up showed that all 
levels were fused after an average of 5.2 months. less 
than 50% of the original fusion mass remained visible on 
2D-cT scans after six months in 64% of fusions grafted 
with osteofil, compared with 21% of fusions grafted with 
vitoss (stryker, Mahwah, New Jersey), which suggested a 
quicker resorption rate of vitoss. This study provides level 
Iv evidence that osteofil may be used as a bone graft 
extender with autologous bone for cervical spinal fusion.
Thoracic spinal fusion. Grafton DBM was the only prod-
uct also used for thoracic fusions. In a retrospective 
cohort, Weinzapfel et al46 used Grafton DBM in patients 
who underwent anterior thoracic discectomies and com-
pared their results with using morsellised cancellous 
allografts. on the final radiographs, 82% of the allograft 
group and 92% of the Grafton DBM group were rated as 
fused. There was no significant difference between the 
two groups. This study provides level III evidence that 
Grafton DBM may be used as a bone graft substitute for 
thoracic spinal fusion.
Trauma surgery. Four DBM products have been used 
to treat bone defects that accompany fractures or were 
the result of nonunion: Allomatrix, DBX (DePuy synthes, 
Zuchwil, switzerland), Grafton DBM and orthoBlast 
(citagenix). They are used as a graft extender in most 
cases, however, they may also be used as a graft substitute.
Fractures. Allomatrix was used to treat distal radial frac-
tures. In a rcT,17 unstable distal radial fractures were 
treated by operative fixation with Kirschner-wires, with 
(n = 24) or without (n = 26) augmentation of the fracture 
site with Allomatrix. The physical and radiological out-
comes did not show any significant difference between 
wrist function, speed to recovery, union rate, or complica-
tion rate during a one-year follow-up. Allomatrix has also 
been used for primary treatment of fresh bone defects 
caused by small-calibre gunshot wounds in the hand. In 
a retrospective case series of 12 patients, 11 bone defects 
healed without further intervention and one defect 
required a second bone grafting procedure.20 In another 
case report, Allomatrix was used to fill metaphyseal bone 
defects after elevation of the impressed osteochondral 
fragments in the treatment of reverse Hill-sachs lesions 
of the humeral head.18 These studies include level I evi-
dence that Allomatrix is not a useful bone graft substitute 
to treat unstable distal radial fractures already fixed with 
Kirschner-wires.
DBX has been used to treat sternal segment disloca-
tions.30,31 sternal segment dislocations in eight patients 
were treated with titanium screws and DBX. Titanium 
screws and DBX reduced the length of hospitalisation, 
and led to rapid functional recovery and excellent aes-
thetic results according to the authors.31 This study pro-
vides level Iv evidence that DBX may be used as a bone 
graft substitute to treat fractures of the sternum.
Grafton DBM and orthoBlast were applied as a bone 
graft extender by cheung et  al.48 Grafton DBM or 
orthoBlast were mixed with cancellous allografts and 
used to graft bone defects encountered in periarticular 
fractures of the tibia, fibula, femur, humerus, forearm and 
acetabulum. Fracture healing occurred in 69% of the 
patients who received Grafton DBM (n = 13) compared 
with 100% in patients who received orthoBlast (n = 15). 
Grafton DBM mixed with cancellous allograft was also 
used to graft bone defects to stimulate bone healing in 
smokers and non-smokers.66 After an average follow-up 
of 32 months, treatment was successful in 68% of the 
smokers compared with 88% of the non-smokers. Four 
patients with foot and ankle fractures (tibial/fibular frac-
ture, fifth metatarsal fracture) were grafted with Grafton 
DBM and autografts. No complications were described.56 
Grafton DBM was also used to enhance cancellous allo-
grafts in two tibial stress fractures treated by drilling and 
bone grafting,52 and for reconstructing large segmental 
bone defects of the tibia (n = 2)50 and humerus (n = 1),51 
using a titanium mesh cage filled with Grafton DBM and 
cancellous allograft chips. These studies include level III 
evidence that both Grafton DBM and orthoBlast may be 
used in combination with allograft as a bone graft substi-
tute to treat bone defects during fracture surgery.
Nonunion. Allomatrix, mixed with cancellous allograft 
chips, was used to treat 41 atrophic or avascular non-
unions. These nonunions were located in the femur, radius, 
tibia, and humerus. In 13 cases the nonunion recurred 
(32%), and revision surgery was necessary in 19 cases.21 
Additionally, Allomatrix has been used to graft bone 
defects that resulted after nonunion (n = 35).23 Allomatrix 
was mixed (1:3) with calcium sulphate pellets, and after 
seven months, 85% of the grafted nonunions were healed. 
These studies provide level Iv evidence that Allomatrix may 
be used as a bone graft substitute to treat nonunion.
DBX has been described in a case report, showing the 
successful treatment of a subtrochanteric nonunion of an 
11-year-old patient with an adult proximal humeral lock-
ing plate and additional grafting with DBX.32 This study 
provides level Iv evidence that DBX may be used as a 
bone graft substitute to treat nonunion.
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Grafton DBM was used in a cohort study by Hierholzer 
et al.53 Treatment of 33 humeral nonunions with Grafton 
DBM were compared with 45 nonunions that received 
autologous bone grafts. Autologous bone grafts resulted 
in union in all cases, whereas Grafton DBM resulted in 
union in 97% in a mean time to union of 4.2 and 4.5 
months, respectively. Ziran et al21,49 described the use of 
Grafton DBM to treat nonunion in two studies. First, 
Grafton DBM was mixed with cancellous allograft to 
stimulate bone healing in smokers and non-smokers.66 
After an average follow-up of 32 months, treatment was 
successful in 68% of the smokers versus 88% of the non-
smokers. subsequently, treatment of nonunion in smok-
ers with Grafton DBM (n = 25) was compared with 
orthoBlast (n = 13).49 Treatment with Grafton DBM was 
only successful in 52%, whereas treatment with 
orthoBlast was successful in 85%, which was not a statis-
tically significant difference. In a case report,54 Grafton 
DBM was used to treat a non-displaced coracoid fracture. 
After screw fixation, the nonunion site was debrided and 
successfully grafted with Grafton DBM. These studies 
include level III evidence that Grafton DBM may be used 
as a bone graft substitute to treat nonunion and level Iv 
evidence that Grafton DBM or orthoBlast may be used as 
a bone graft extender to treat nonunion.
Orthopaedic surgery. Four DBM products, Allomatrix, 
DBX, Grafton DBM, and orthoBlast, have been described 
for other clinical indications that included the treatment 
of arthrodesis, avascular necrosis, and tumour treatment.
Allomatrix was added to a calcium sulphate bone sub-
stitute (osteoset) in a small case series by Deheshi, Allen 
and Kim,12 to be used as a graft to restore retroacetabular 
bone stock in seven patients who showed retroacetabu-
lar osteolysis after primary total hip arthroplasty with 
cementless acetabular sockets. specific graft-related out-
comes were not reported.12 These studies provide level Iv 
evidence that Allomatrix can be used as a bone graft 
extender to treat acetabular bone defects.
Allomatrix has been used to treat benign bone tumours 
in the tibia (n = 17), humerus (n = 11), fibula (n = 3), and 
radius (n = 2). Defects were filled with a mixture of 
Allomatrix and a calcium sulphate bone substitute 
(osteoset, 1:3). After seven months, 93% of the bone 
defects were healed, tumour recurrence was seen in three 
cases, and one wound infection required antibiotic treat-
ment.23 In addition, in a study that investigated the treat-
ment of 98 benign bone tumours located in the tibia, 
humerus, femur and pelvis with various bone grafts, 
Allomatrix was used in 34 of these grafting procedures but 
no Allomatrix-specific outcomes were reported.28 These 
studies provide level Iv evidence that Allomatrix may be 
used as a bone graft substitute with or without a calcium 
sulphate bone substitute to treat benign bone tumours.
DBX was used as a graft in the treatment of enchon-
dromas of the hand. Kwon and Wong,34 and Dietz, 
Kachar and Nagle,33 reported small case series of five and 
two patients, respectively. No recurrence or pathological 
fractures were reported. These studies provide level Iv 
evidence that DBX may be used as a bone graft substitute 
to treat hand enchondromas.
Grafton DBM has been described in ankle and foot sur-
gery. In a case series by Kado, Gambetta and Perlman, 
Grafton56 DBM was combined with autologous or allo-
genic bone for arthrodesis (n = 18) or osteotomies 
(n = 6). In addition, Grafton DBM (n = 37) and orthoBlast 
(n = 26) were also used for complex ankle or hindfoot 
arthrodesis.55 Nonunions developed in five patients who 
had Grafton DBM (14%) and in two patients who had 
orthoBlast (8%). Furthermore, Grafton DBM was used as 
a bone graft after core decompression of asymptomatic 
avascular necrosis of the hip in 37 patients,57 but it did 
not reduce the need for total hip arthroplasty compared 
with treatment of symptomatic avascular necrosis during 
the two years of follow-up. Finally, Grafton DBM was 
used in combination with autologous bone marrow for 
percutaneous injection of unicameral bone cysts in 33 
patients. After six weeks, patients returned to everyday 
activity, and bone healing was confirmed radiologically 
after six months.59 Furthermore, solitary bone cysts in 
children could be treated with Grafton DBM.60,62 After fill-
ing the defects with Grafton DBM in seven cases, a con-
tinuous decrease in radiographic bone transparency was 
observed over a period of two years.60 These studies 
include level Iv evidence that Grafton DBM can be used 
as a bone graft substitute with or without autologous 
bone marrow to treat benign bone tumours.
Discussion
The aim of this systematic review was to provide the clini-
cal level of evidence for using DBM products in trauma 
and orthopaedic surgery. This review reveals that the 
clinical level of evidence is mainly limited to level Iv stud-
ies: case series in which DBM products are described for 
numerous indications with or without additional auto-
grafts, allografts or calcium-based bone substitutes. 
combined with the fact that the composition and amount 
of osteo-inductive growth factors may vary extensively 
between and within DBM products,8,67 it is not possible 
to point out specific indications where DBM products 
have added value in trauma and orthopaedic surgery. 
Formulating an evidence-based guideline to assist trauma 
and orthopaedic surgeons requires more well designed 
clinical studies that prove a beneficial effect of DBM com-
pared with treatment with a bone graft substitute (nega-
tive control) or treatment including the current gold 
standard autografts (positive control).
The clinical use of DBM is most thoroughly described 
for cervical and lumbar spinal fusion surgery.68 In a sys-
tematic review by Zadegan et  al69 which included 12 
studies, the fusion rate of DBM in cervical fusion surgery 
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was comparable with that of other graft materials. 
However, most studies did not specify which DBM prod-
uct was used, which may possibly lead to false claims of 
the effect of specific DBM products. This review shows 
that there is only one level I study available that deter-
mines the effect of Grafton DBM in cervical fusion sur-
gery.41 However, this study shows a higher rate of 
nonunion compared with that found in autologous bone 
grafting when it is used in cervical spine fusions. In 
another rcT, Grafton DBM was used in lumbar spinal 
fusion,35 showing that similar fusion rates were achieved 
when Grafton DBM was added to autologous bone ver-
sus autologous bone alone. Except for Allomatrix, there is 
hardly any evidence for using other DBM products in spi-
nal fusion surgery.
The clinical use of DBM products in trauma surgery is 
not well supported. For example, the use of DBX is only 
described in a small case series of sternum fractures30 and 
a single case report of nonunion.32 Furthermore, the case-
control study that used Grafton DBM or orthoBlast in 
fracture treatment48 included only 13 and 15 cases and 
did not have a control group. The rcT by Hierholzer 
et al53 which concludes that grafting humeral nonunions 
with Grafton DBM is as effective as using autologous bone 
reported union rates of 97% and 100%, respectively, after 
four months. These high union rates in both groups raise 
the question as to whether the re- osteosynthesis per-
formed has not been the most critical factor in achieving 
union. This is in line with recent publications regarding 
the treatment of nonunion70 that indicate that optimising 
mechanical stability is often the key factor in achieving 
union. Although using autologous bone grafts for treat-
ment of post-traumatic bone defects seems to be effec-
tive,71 this cannot yet be concluded for using DBM or 
specific DBM products and therefore warrants further 
investigation.
The clinical use of DBM in other orthopaedic indica-
tions, such as arthrodesis, avascular necrosis or tumour 
treatment, is described in surprisingly few studies. For 
example, there are only two case series found that describe 
the use of DBM in foot or ankle arthrodesis.55,56 Foot and 
ankle arthrodesis are known to have a high nonunion rate 
leading to poor functional outcomes,72 however, whether 
DBM is capable of reducing the nonunion rate, similar to 
autologous bone grafts,73 remains unknown.
In addition to the limited clinical evidence for using 
DBM products in trauma- and orthopaedic-related indi-
cations, several other important drawbacks of DBM have 
to be considered. The most significant drawback is the 
possible difference of growth factor concentrations 
between and within DBM products. Bae et  al8 showed 
significant lot-to-lot variability of single DBM products 
with regard to BMP concentrations and in vivo fusion 
rates in rats. Another study by Bae et al67 showed that the 
variability of BMP concentrations among different lots of 
the same product exceeded the variability of BMP con-
centrations among different products. The different BMP 
concentrations might be explained through donor-
related factors or preparation methods. Donor variability 
in terms of age and gender affect the osteo-inductive 
potential of derived DBM products.74,75 More impor-
tantly, preparation methods such as sterilisation through 
gamma irradiation or hydrogen peroxide exposure 
reduce the osteo-inductive potential in in vitro and in vivo 
rat models.76,77 Also, the carrier materials used can affect 
its potential. reduced osteo-inductive potential has been 
observed for glycerol carriers which generate a highly 
acidic environment for host tissues.78 All of these results 
underline the necessity of studying the clinical effect of 
DBM in a product-specific manner.
The limitations of this systematic review that should be 
taken into account are related to the search method. First, 
the inclusion of DBM products within this review is based 
on the commercial availability within the Netherlands. 
However, the authors believe that the most commonly 
used products (Allomatrix, DBX, and Grafton DBM) are 
included. Furthermore, there is no official international 
database where all available DBM products are regis-
tered. This makes it difficult to include every possible 
DBM product. secondly, despite the search terms used 
here, articles may have been overlooked if the use of a 
specific DBM product was not clearly stated within the 
methods section. This cannot be avoided by adjusting 
the search strategy. Instead, it is the author’s responsibil-
ity to state clearly which DBM product they have used in 
their study. Finally, the broad inclusion criteria resulted in 
heterogeneity among the included studies. This hetero-
geneity made it impossible to perform a meta-analysis on 
the overall clinical effect of DBM in trauma and orthopae-
dic surgery.
In conclusion, preclinical studies have shown that the 
in vitro and in vivo efficacy of DBM depends upon the 
preparation methods and carrier materials used. Due to 
these differences, it is important for trauma and ortho-
paedic surgeons to make evidence-based decisions based 
on available literature that specifies the DBM product 
used for each indication. This review provides an up-to-
date overview of the currently available clinical evidence 
for 17 different DBM products. overall, the level of evi-
dence of the studies available to date is generally low, 
mainly including retrospective case series. The highest 
clinical level of evidence is available for using DBM prod-
ucts in spinal surgery where its performance is compara-
ble with that of autologous bone grafting for lumbar 
spinal fusions only (level I). The clinical level of evidence 
for using DBM products in trauma surgery is minimal 
(mainly level Iv). Thus, no evident benefit is proven for 
treatment of fractures or nonunion. The same holds for 
orthopaedic indications such as arthrodesis, avascular 
necrosis, and tumour surgery. Therefore, there is a need 
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for more level I (rcTs or prospective case-cohort) studies 
in order to understand clearly the clinical effects of DBM 
in trauma and orthopaedic surgery, and to stimulate the 
discussion regarding the effectivity of using DBM in 
trauma and orthopaedic surgery.
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